Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of WXFL10203614 in moderate-to-severe atopic dermatitis
CTR20263666Phase 3Active
- Sponsor
- Wuxi Fortune Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of WXFL10203614 in atopic dermatitis (AD), sponsored by Wuxi Fortune Pharmaceutical Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
WXFL10203614
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263666.